A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
Completed · Phase 1 · NCT07165015
Conditions: Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD)
At a glance
- Research payments reported, 2025
- $580,576
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 31
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3537031 (drug)
- Dates
- Started 2025-09-18; completion 2026-04-16
- Results posted
- Not yet
The purpose of this study is to assess the amount of LY3537031 that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants.
From ClinicalTrials.gov, last updated 2026-04-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $580,576 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kwabena Ayesu, MD Internal Medicine · Orlando, FL
- Thomas C. Marbury, M.D. Nephrology (Kidney) · Orlando, FL
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Omega Research Orlando LLC $453,288
- Orlando Clinical Research Center Inc $127,288
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.